J
Jianming Wang
Researcher at Amgen
Publications - 6
Citations - 1198
Jianming Wang is an academic researcher from Amgen. The author has contributed to research in topics: Denosumab & Zoledronic acid. The author has an hindex of 4, co-authored 6 publications receiving 1094 citations.
Papers
More filters
Journal ArticleDOI
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
David H. Henry,Luis Costa,François Goldwasser,Vera Hirsh,Vania Hungria,Jana Prausova,Giorgio V. Scagliotti,Harm Sleeboom,Andrew Spencer,Saroj Vadhan-Raj,Roger von Moos,Wolfgang Willenbacher,Penella J. Woll,Jianming Wang,Qi Jiang,Susie Jun,Roger Dansey,Howard S. Yeh +17 more
TL;DR: Denosumab was noninferior (trending to superiority) to ZA in preventing or delaying first on-study SRE in patients with advanced cancer metastatic to bone or myeloma and represents a potential novel treatment option with the convenience of subcutaneous administration and no requirement for renal monitoring or dose adjustment.
Journal ArticleDOI
20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
David H. Henry,R. von Moos,Saroj Vadhan-Raj,Vania Tm Hungria,Andrew Spencer,Vera Hirsh,Jianming Wang,Susie Jun,Howard S. Yeh,Roger Dansey +9 more
Journal ArticleDOI
Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer.
David H. Henry,R. von Moos,V. Hungria,Luís Costa,Penella J. Woll,G.V. Scagliotti,Jianming Wang,Susie Jun,Roger Dansey,Howard S. Yeh +9 more
TL;DR: This data indicates that in patients with solid tumor-related bone metastases, cancer cells stimulate RANKL-induced, osteoclast-mediated bone destruction, increasing the risk of skeletal-related events (SR...
Journal ArticleDOI
Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial.
Saroj Vadhan-Raj,David H. Henry,R. von Moos,Vania Tm Hungria,François Goldwasser,G.V. Scagliotti,Jianming Wang,Susie Jun,Roger Dansey,Howard S. Yeh +9 more
TL;DR: This phase III, randomized, double-blind, study compared denosumab and zoledronic acid with respect to SREs in patients (pts) with metastatic disease and found denosumsumab was non-inferior to ZA in time to first on- study SRE.
Journal ArticleDOI
Reply to S.M. Sorscher et al
David H. Henry,Luis Costa,François Goldwasser,Vera Hirsh,Vania Tm Hungria,Jana Prausova,Giorgio V. Scagliotti,Harm Sleeboom,Andrew Spencer,Saroj Vadhan-Raj,Roger von Moos,Wolfgang Willenbacher,Jianming Wang,Qi-Zhong Jiang,Susie Jun,Roger Dansey,Howard S. Yeh +16 more